A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
A Drug Drug Interaction Study Between PF-06826647 And Oral Contraceptive Steroids In Healthy Female Participants
This is a Phase 1, fixed sequence, multiple dose, open label study of the effect of
 PF-06826647 on oral contraceptive (OC) pharmacokinetics (PK) and vice versa in healthy female
 participants. A total of approximately 15 healthy female participants will be enrolled and
 dosed to achieve at least 12 participants completing the study.
Inclusion Criteria:

 -  1. Healthy female participants of non-childbearing potential must be 18 to 60 years of
 age, inclusive

 -  2. Female participants who are overtly healthy as determined by medical evaluation
 including medical history, physical examination, including blood pressure (BP) and
 pulse rate measurement, laboratory tests, and 12 lead ECG

 -  3. Participants who are willing and able to comply with all scheduled visits,
 treatment plan, laboratory tests, lifestyle considerations, and other study procedures

 -  4. Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110
 lb)

 Exclusion Criteria:

 -  1. Evidence or history of clinically significant hematological, renal, endocrine,
 pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or
 allergic disease (including drug allergies, but excluding untreated, asymptomatic,
 seasonal allergies at the time of dosing).

 -  2. Any condition possibly affecting drug absorption (eg, gastrectomy,
 cholecystectomy).

 -  3. History of venous and arterial thrombosis (ie, deep venous thrombosis, pulmonary
 embolism) or hereditary clotting disorders (in first degree immediate relatives).

 -  4. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis
 C; positive testing for HIV, hepatitis B surface antigen (HBsAg), or hepatitis C
 antibody (HCVAb). Hepatitis B vaccination is allowed.

 -  5. Any current evidence of untreated active or latent or inadequately treated
 infection with Mycobacterium tuberculosis (TB).

 -  6. Participants who use tobacco or nicotine containing products.